| Add to balance / Manage account | User: | Log out |
| Prospect News home > News index > List of issuers P > Headlines for Possis Medical, Inc. > News item |
Possis study finds AngioJet thrombectomy in heart attack patients safe, may improve outcomes
By Elaine Rigoli
Tampa, Fla., June 28 - Possis Medical, Inc. said new observational studies of its AngioJet thrombectomy system for treating heart attack patients are being published as a supplement to the July issue of The Journal of Invasive Cardiology.
The supplement details "real-world" results from five patient registries presented by a panel of interventional cardiologists during the March annual convention of the American College of Cardiology in Atlanta.
Possis said these registry results led the panel to conclude in part that "use of the AngioJet with primary percutaneous catheter-based intervention (PCI) is safe and suggest that the AngioJet may improve procedural and clinical outcomes in a broad spectrum of real-world ST-elevation myocardial infarction patients treated with primary PCI."
"The patient registries highlighted in this supplement show the effectiveness and safety of using AngioJet to treat heart attack patients with large thrombus. This is an important step in helping physicians understand the clinical value AngioJet brings to the treatment of coronary thrombus in a variety of settings," chief executive officer Robert G. Dutcher said in a news release.
The panel also commented on the favorable results of these registries compared to the AiMI trial results announced in 2004, suggesting that the mortality and major adverse cardiac event rates were higher with rheolytic thrombectomy than with the control.
However, the study was not powered to detect differences in clinical events, so the findings were quite surprising, the panel said.
The differences in mortality were not due to a high mortality in the AngioJet arm, but rather to an unexpectedly low mortality in the control arm (0.8%, lower than any previously reported primary PCI trial).
Located in Minneapolis, Possis develops, manufactures and markets medical devices for the cardiovascular and vascular treatment markets.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.